News stories about Ardelyx (NASDAQ:ARDX) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ardelyx earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.8566848339437 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Analysts recommended an average rating score of 1.30 for Ardelyx, Inc. (ARDX) – Wall Street Morning (wallstreetmorning.com)
- Ardelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China – StreetInsider.com (streetinsider.com)
- BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China (reuters.com)
- Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China (finance.yahoo.com)
- Ardelyx, Inc. (ARDX) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
Several brokerages have weighed in on ARDX. Wedbush reissued an “outperform” rating and set a $12.00 price target (down previously from $13.00) on shares of Ardelyx in a research report on Tuesday, November 28th. ValuEngine cut shares of Ardelyx from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reissued a “buy” rating and set a $12.00 price target on shares of Ardelyx in a research report on Tuesday, November 21st. Ladenburg Thalmann Financial Services dropped their price target on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, November 22nd. Finally, Zacks Investment Research raised shares of Ardelyx from a “sell” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.64.
Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.10. During the same quarter in the previous year, the firm posted ($0.65) EPS. sell-side analysts forecast that Ardelyx will post -2.01 earnings per share for the current year.
In other Ardelyx news, COO Reginald Seeto sold 10,008 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $5.20, for a total value of $52,041.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.47% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by Week Herald and is owned by of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2017/12/14/ardelyx-ardx-earning-somewhat-positive-news-coverage-accern-reports.html.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.